Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Fennec Pharmaceuticals Inc
FENC | US
4.66
USD0.12
2.64%
FENC | US
About Fennec Pharmaceuticals Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
21/10/2024
Close
4.66
Open
4.62
High
4.68
Low
4.60
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. The company's product candidates include PEDMARK a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity hearing loss in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park North Carolina.
View LessFENC | US
Risk
50.1
Sharpe
-0.73
Luna's Score
54/100
Recommendation
Hold
Luna says (FENC | US)
What's Working
Low Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Strong Revenue Growth (> 10%)
What's not Working
Microcap (<300M USD)
Rich in Valuation (Price to Book > 8)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
48.2%1 month
50.1%3 months
50.3%6 months
59.3%Returns
Fundamental Ratios
PE
64.86
Fwd. PE
10.62
Price to book
57.93
Debt to equity
-21.93
Debt to assets
0.47
Ent. to EBITDA
17.50
Ent. to rev.
2.36
PEG
-
Other Fundamentals
EBITDA
-13.01M
MarketCap
131.31M
MarketCap(USD)
131.31M
Div. yield
-
Op. margin
-69.39
Erngs. growth
-
Rev. growth
118.40
Ret. on equity
-1.01K
Short ratio
19.88
Short perc.
9.87
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Range10D
0.77
Range1M
1.24
Range3M
2.64
Volumes: Market Activity
Rel. volume
0.88
Price X volume
285.47K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 17.50 | - | Expensive |
| Ent. to Revenue | 2.36 | - | Cheaper |
| PE Ratio | 64.86 | 41.03 | Expensive |
| Price to Book | 57.93 | 15.55 | Expensive |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 50.26 | - | Lower Risk |
| Debt to Equity | -21.93 | -1.23 | Cheaper |
| Debt to Assets | 0.47 | 0.25 | Expensive |
| Market Cap | 131.31M | - | Emerging |
